Phase 1, Open-label, Single-dose Study to Characterize the Elimination of Guselkumab Glycoform Variants in Healthy Subjects

Trial Profile

Phase 1, Open-label, Single-dose Study to Characterize the Elimination of Guselkumab Glycoform Variants in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Apr 2016

At a glance

  • Drugs Guselkumab (Primary)
  • Indications Erythrodermic psoriasis; Palmoplantar pustulosis; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis
  • Focus Pharmacokinetics
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 11 Apr 2016 Status changed from recruiting to completed.
    • 28 Oct 2015 Status changed from not yet recruiting to recruiting according to ClinicalTrials.gov record.
    • 10 Oct 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top